Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124952182 | 12495218 | 2 | F | 20160901 | 20160624 | 20160902 | EXP | US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-050958 | BRISTOL MYERS SQUIBB | 85.00 | YR | F | Y | 0.00000 | 20160902 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124952182 | 12495218 | 1 | PS | ELIQUIS | APIXABAN | 1 | Oral | 2.5 MG, BID | U | U | 202155 | 2.5 | MG | BID | |||||
| 124952182 | 12495218 | 2 | SS | COUMADIN | WARFARIN SODIUM | 1 | Unknown | U | 0 | ||||||||||
| 124952182 | 12495218 | 3 | SS | ASPIRIN. | ASPIRIN | 1 | Unknown | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124952182 | 12495218 | 1 | Product used for unknown indication |
| 124952182 | 12495218 | 2 | Product used for unknown indication |
| 124952182 | 12495218 | 3 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124952182 | 12495218 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124952182 | 12495218 | Contraindicated product administered | |
| 124952182 | 12495218 | Epistaxis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |